Selexipag for schistosomiasis-related pulmonary hypertension
Part of Infections, Lungs & breathing clinical trials.
This study looks at the long-term effects of a medicine called selexipag on people with pulmonary hypertension caused by schistosomiasis, a parasitic infection. It aims to see if selexipag improves outcomes compared to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of pulmonary hypertension linked to schistosomiasis, proven by a heart catheter test.
- You must have evidence of schistosomiasis infection, such as a history of the infection and liver or spleen changes seen on an ultrasound.
- You must have received treatment for schistosomiasis in the past.
- Your condition must be stable, meaning no serious heart issues or worsening symptoms in the last 12 weeks.
- You must be in WHO functional class I to III (able to do some activity without severe symptoms), and be on stable PAH-specific medication like a PDE5 inhibitor or ERA for at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two approaches for people with PAH whose current treatment (a combination of sildenafil and an endothelin receptor antagonist) needs to be stepped up. Half the participants will add a third medicine (iloprost or selexipag), while the other half will increase their sildenafil dose. The goal is to see which strategy works better for improving symptoms and lowering risk.
This study looks at how patients feel and how well they stick to treatment when switching from an inhaled medication (iloprost) to a pill (selexipag) for pulmonary arterial hypertension (high blood pressure in the lungs). If you are already switching, your experiences can help doctors understand the benefits and challenges of this change.
This study tests whether switching from the oral medicine selexipag to an inhaled medicine called treprostinil can improve symptoms or side effects in people with pulmonary arterial hypertension (PAH). It may be an option if you are not getting enough benefit or are having trouble tolerating selexipag.
This trial tests if artesunate, a malaria drug, is safe and tolerable for people with pulmonary arterial hypertension (PAH). It may offer a new treatment option for PAH patients whose symptoms persist despite using two or more standard therapies.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This study looks at how a medication called sotatercept affects the blood vessels in the lungs over time. It aims to see if it can help improve how the heart and lungs work in people with pulmonary hypertension.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.